Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04461496
Other study ID # FMJ
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 30, 2020
Est. completion date June 5, 2025

Study information

Verified date June 2020
Source Meshalkin Research Institute of Pathology of Circulation
Contact Andrey A Karpenko, PHD
Phone 89139504100
Email a_karpenko@meshalkin.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypothesis: "Total" endovascular revascularization of a multistory lesion of the iliac-femoral-popliteal segment is safer and a better quality of life is achieved in comparison with hybrid intervention.

The lack of damage to the skin avoids complications in the postoperative and remote periods of observation, thereby improving the quality of life


Description:

Mortality from cardiovascular disease occupies a leading position worldwide. Patients with atherosclerotic lesions of the peripheral arteries account for 20% of the total number of patients with cardiovascular diseases. Special attention should be paid to patients with multilevel lesions artery since the maximum reduction in blood flow leads to the development of critical limb ischemia (CLI) and a high risk of limb loss. Almost 25% of patients with CLI require multistory revascularization of the arteries of the lower extremities. In this group of patients, proximal revascularization of the only iliac segment is usually the initial approach, but in some cases leads to disappointing relief of symptoms due to concomitant severe lesions of the infra-anginal arteries. Whereas the combined implementation of femoral-popliteal bypass surgery or endovascular revascularization of SFA can increase the likelihood of ulcer healing and avoid multi-stage surgical interventions. In turn, an adequate inflow to the revascularized segment is necessary for its long-term functioning.

Femoral-popliteal bypass surgery is still the procedure of choice for long occlusions of the superficial femoral artery TASC C, D. The "total" endovascular correction (full metal jacket) may become an alternative to hybrid technology since allows for less traumatic and fully revascularization of the wall occlusal lesions of SFA. The salvation of the limb and the achievement of compensation for the clinic of chronic lower limb ischemia in patients with multi-vessel atherosclerotic lesions of the arteries of the lower extremities is possible using both hybrid procedures and endovascular reconstruction. The main goal of stenting the iliac arteries during hybrid procedures is not only to restore blood flow in the common and deep femoral arteries but also to support the long-term functioning of the femoral-popliteal shunt or stent in SFA.

Similar analogues of the comparative study of the two methods of revascularization in the world literature the investigators have not seen.

In the first group, stenting of the iliac artery under x-ray control with the bypass of the femoral-popliteal segment above the gap of the knee joint is performed. The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area. In the postoperative period, clexane is administered at a prophylactic dosage of 3 days and cardiomagnyl at a dosage of 75 mg per day. Next, the patient takes dual antiplatelet therapy cardiomagnyl 75 mg + clopidogrel 75 mg for 6 months.

In the second group, stenting of the iliac artery and recanalization SFA with angioplasty and stenting under X-ray control is performed. The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area. In the postoperative period, a loading dose of clopidogrel 300 mg + cardiomagnyl 75 mg is taken. Next, the patient takes dual antiplatelet therapy cardiomagnyl 75 mg + clopidogrel 75 mg for 6 months.

Statistical analysis: Data processing and comparison of variables will be carried out by appropriate statistical methods with a preliminary check for compliance of the sign variability with the normal distribution, which is evaluated by the Kolmogorov-Smirnov criterion. Under the condition of the normal distribution, Student's criterion is used. A comparative assessment of qualitative characteristics is carried out using the χ2 criterion. The dynamics of the indicators in the group will be determined by the pairwise coupled option using the Student criterion with a normal distribution of indicators and using the Wilcoxon criterion - with a mismatch with the normal distribution. Comparison according to qualitative characteristics (gender, degree of ischemia, and others) will be carried out using the criteria of Pearson (Pearson) and Fisher (Fisher). In all cases, a 95% significance level is used.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 5, 2025
Est. primary completion date June 5, 2025
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria:

- patients with multisegment lesions of the iliac-femoral-popliteal segment, with the distal border of the lesion above the slit of the knee joint.

- chronic ischemia 3-6 (according to Rutherford),

- the satisfactory direction of the outflow.

- Patients who gave consent to participate in this study

Exclusion Criteria:

- Chronic occlusion of the SFA at least 2cm

- Heavy calcification of SFA • Infection in the area of the access artery

- Expressed, more than 50% stenotic lesions of the infrarenal aorta

- Prolonged loss (TASC D) iliac artery on the side of revascularization

- aneurysmal widening of the infrarenal aorta and iliac arteries

- Hemodynamically significant lesions DFA

- Chronic heart failure III-IV functional class NYHA classification;

- decompensated Chronic "pulmonary" heart; • Severe hepatic or renal insufficiency (bilirubin >35 mmol/l, glomerular filtration rate <60 ml/min);

- Polyvalent drug Allergy;

- Malignant cancer in the terminal stage with a projected life span of 6 months;

- Acute stroke;

- a Pronounced calcification of the arteries of the lower limbs;

- Patients with significant lesions of the common femoral artery

- the Refusal of a patient to participate or continue to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Hybrid revascularization
The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
Full metall Jacket
The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.

Locations

Country Name City State
Russian Federation Meshalkin Research Institute of Pathology of Circulation Novosibirsk Novosibirskaya Obl

Sponsors (1)

Lead Sponsor Collaborator
Meshalkin Research Institute of Pathology of Circulation

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of the procedure freedom from thrombosis was defined as the absence of occlusion by duplex ultrasonography or CT angiography of the treated segment 24 months
Primary Safety of the procedure bleeding according to blood loss volume (millilitres) 1. intraoperative blood loss volume; 2.Postoperative blood loss volume by duplex ultrasonography and drainage losses 30 days
Primary Safety of the procedure major adverse limb events according to clinical evaluation 24 months
Secondary Primary patency Primary patency rate at 24 months follow-up 24 months
Secondary Secondary patency Secondary patency rate at 24 months follow-up 24 months
Secondary Changes in the patients quality of life: questionnaire improving the quality of life in accordance with the questionnaire "The Short Form-36" for 24 months. The indicators of each scale are designed in such a way that the higher the value of the indicator (from 0 to 100), the better the score on the selected scale 24 months
Secondary Success of the procedure the number of successful attempts 1 month
Secondary Changes in chronic lower limb ischemia at 24 months follow-up Number of cases of improvement of at least 1 category of Rutherford classification for claudicants 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03121430 - Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion N/A
Completed NCT01327950 - Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions N/A
Completed NCT05451485 - VFI in Healthy Vessels
Not yet recruiting NCT04175197 - LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries
Withdrawn NCT05079906 - Assessment of Superficial Femoral Artery Lesions With FFR From the ACIST Navvus® Catheter N/A
Recruiting NCT04971772 - SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries
Recruiting NCT04434586 - Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions N/A
Recruiting NCT05291247 - Shockwave IVL + DES
Completed NCT01602159 - Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST) N/A
Not yet recruiting NCT06410313 - First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease N/A
Terminated NCT00908947 - CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM") N/A
Recruiting NCT05132361 - SELUTION4SFA Trial N/A
Completed NCT01336101 - Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent N/A
Recruiting NCT06416644 - The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry) N/A